The DOI matches its Crossref record; 244 of the 249 references it cites were found in a registry or an index.
Drug repositioning: Progress and challenges in drug discovery for various diseases
Open accessAbstract
Compared with traditional de novo drug discovery, drug repurposing has become an attractive drug discovery strategy due to its low-cost and high efficiency. Through a comprehensive analysis of the candidates that have been identified with drug repositioning potentials, it is found that although some drugs do not show obvious advantages in the original indications, they may exert more obvious effects in other diseases. In addition, some drugs have a synergistic effect to exert better clinical efficacy if used in combination. Particularly, it has been confirmed that drug repositioning has benefits and values on the current public health emergency such as the COVID-19 pandemic, which proved the great potential of drug repositioning. In this review, we systematically reviewed a series of representative drugs that have been repositioned for different diseases and illustrated successful cases in each disease. Especially, the mechanism of action for the representative drugs in new indications were explicitly explored for each disease, we hope this review can provide important insights for follow-up research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yet, the conventional pathway for novel drug discovery, development, and regulatory approval can span approximately 15 years, rendering it inadequate to address the immediate and growing clinical demands posed by resistant Candida infections [14, 15].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Completing these stages can take approximately 12–17 years [14].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Smithburn, K. C. (1952) · The Journal of Immunology · doi:10.4049/jimmunol.69.2.223 · Cited by 3,553
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,367
Self-citation
Research works printed but not linked: 12
- Shahnawaz Khan, 2012, 11, 369
- Rascol, 2021, 20, 1048
- Naccarati, 2012, 2, 211
- Chen, 2011, 6, 27186
- Schmidmaier, 2007, 79, 240
- Leonardi, 2018, 52, 1071
- Niu, 2002, 21, 7001
- Riedel, 2017, Drug repurposing approach identifies a synergistic drug combination of an antifungal agent and an experimental organometallic drug for melanoma treatment, Mol. Pharm., 116
- You, 2018, 28, 492
- Alsterholm, 2010, 90, 239
- Pippi, 2019, 27, 41
- Barrows, 2016, A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe, 259, 10.1016/j.chom.2016.07.004 · DOI
Cited by
Sorted by citations
Bai, R., Li, Y., Jian, L., Yue-hui, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 296
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064732 · Cited by 168
KG-Predict: A knowledge graph computational framework for drug repurposing
Gao, Z., Ding, P., & Xu, R. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104133 · Cited by 103
Triclosan: A Small Molecule with Controversial Roles
Sinicropi, M. S., Iacopetta, D., Ceramella, J., Catalano, A. A., Mariconda, A., PELLEGRINO, M. A., Saturnino, C., Longo, P., & Aquaro, S. (2022) · Antibiotics · doi:10.3390/antibiotics11060735 · Cited by 96
A comprehensive review of computational cell cycle models in guiding cancer treatment strategies
Ma, C., & Gürkan-Çavusoglu, E. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00397-7 · Cited by 63
Metadata
- Authors
- Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Chen, Yadong
- Zhang, Yanmin
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 234
- Pages
- 114239
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC8883737
- OpenAlex
- W4220885170
- Cited by
- 232
- References
- 249
- Citations by year
- 2026: 35 · 2025: 77 · 2024: 80 · 2023: 31 · 2022: 9
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug repurposing, drug discovery, drug synergy, combination therapy, COVID-19 pandemic, mechanism of action
- MeSH terms
- COVID-19 Drug Treatment, Humans, Drug Discovery, Drug Repositioning, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
